Secondary Hyperparathyroidism in Heart Failure

Mohamed S. Morsy, Dwight Dishmon, Nadish Garg, Karl Weber

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Secondary hyperparathyroidism (SHPT) is a well-known pathophysiologic feature of chronic renal failure. In recent years, SHPT has become recognized as a complication of the aldosteronism associated with congestive heart failure and where excretory Ca2+ and Mg2+ wasting results in plasma-ionized hypocalcemia and hypomagnesemia. Elevations in plasma parathyroid hormone have adverse systemic consequences, including intracellular Ca2+ overloading of myocytes and vascular smooth muscle with the induction of oxidative stress. Herein, we briefly review the presence and adverse outcomes of SHPT in persons with heart failure.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalAmerican Journal of the Medical Sciences
Volume354
Issue number4
DOIs
StatePublished - Oct 1 2017

Fingerprint

Secondary Hyperparathyroidism
Heart Failure
Hyperaldosteronism
Hypocalcemia
Parathyroid Hormone
Vascular Smooth Muscle
Muscle Cells
Chronic Kidney Failure
Oxidative Stress

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Secondary Hyperparathyroidism in Heart Failure. / Morsy, Mohamed S.; Dishmon, Dwight; Garg, Nadish; Weber, Karl.

In: American Journal of the Medical Sciences, Vol. 354, No. 4, 01.10.2017, p. 335-338.

Research output: Contribution to journalArticle

Morsy, Mohamed S. ; Dishmon, Dwight ; Garg, Nadish ; Weber, Karl. / Secondary Hyperparathyroidism in Heart Failure. In: American Journal of the Medical Sciences. 2017 ; Vol. 354, No. 4. pp. 335-338.
@article{2b175ebba1a14b478baa4c0dacfa7db6,
title = "Secondary Hyperparathyroidism in Heart Failure",
abstract = "Secondary hyperparathyroidism (SHPT) is a well-known pathophysiologic feature of chronic renal failure. In recent years, SHPT has become recognized as a complication of the aldosteronism associated with congestive heart failure and where excretory Ca2+ and Mg2+ wasting results in plasma-ionized hypocalcemia and hypomagnesemia. Elevations in plasma parathyroid hormone have adverse systemic consequences, including intracellular Ca2+ overloading of myocytes and vascular smooth muscle with the induction of oxidative stress. Herein, we briefly review the presence and adverse outcomes of SHPT in persons with heart failure.",
author = "Morsy, {Mohamed S.} and Dwight Dishmon and Nadish Garg and Karl Weber",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.amjms.2017.02.008",
language = "English (US)",
volume = "354",
pages = "335--338",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Secondary Hyperparathyroidism in Heart Failure

AU - Morsy, Mohamed S.

AU - Dishmon, Dwight

AU - Garg, Nadish

AU - Weber, Karl

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Secondary hyperparathyroidism (SHPT) is a well-known pathophysiologic feature of chronic renal failure. In recent years, SHPT has become recognized as a complication of the aldosteronism associated with congestive heart failure and where excretory Ca2+ and Mg2+ wasting results in plasma-ionized hypocalcemia and hypomagnesemia. Elevations in plasma parathyroid hormone have adverse systemic consequences, including intracellular Ca2+ overloading of myocytes and vascular smooth muscle with the induction of oxidative stress. Herein, we briefly review the presence and adverse outcomes of SHPT in persons with heart failure.

AB - Secondary hyperparathyroidism (SHPT) is a well-known pathophysiologic feature of chronic renal failure. In recent years, SHPT has become recognized as a complication of the aldosteronism associated with congestive heart failure and where excretory Ca2+ and Mg2+ wasting results in plasma-ionized hypocalcemia and hypomagnesemia. Elevations in plasma parathyroid hormone have adverse systemic consequences, including intracellular Ca2+ overloading of myocytes and vascular smooth muscle with the induction of oxidative stress. Herein, we briefly review the presence and adverse outcomes of SHPT in persons with heart failure.

UR - http://www.scopus.com/inward/record.url?scp=85017410221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017410221&partnerID=8YFLogxK

U2 - 10.1016/j.amjms.2017.02.008

DO - 10.1016/j.amjms.2017.02.008

M3 - Article

VL - 354

SP - 335

EP - 338

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 4

ER -